News

insert an image 968px x 220px

News

Gentronix SOT 2017 Conference Poster

Posted on March 28, 2017 by Chris Hughes

“Utility of the GADD45a Genotoxicity Screening Assays — A Review of 10 Years of Published Data” is now available in our media library.

Read the rest of this news item

Board Changes at Gentronix Ltd.

Posted on November 23, 2016 by Chris Hughes

The Genotoxicity specialist Gentronix is pleased to announce that Dr. Matt Tate has joined the Gentronix Ltd Board as Technical Director, effective 1st November 2016.  Dr Tate joined the company in 2006 and has developed an in-depth knowledge of the field with several publications to his name and an ability to provide quality, customised advice to customers. John Nicholson, Gentronix Chairman, commented that “Matt Tate has developed a terrific awareness of what is current in the genotoxicity field and has become increasingly well regarded in his field and we are confident that he will make a significant contribution to the Gentronix…

Read the rest of this news item

New European Sales Manager

Posted on July 19, 2016 by Chris Hughes

flag

As Gentronix continues to expand its workforce and services we are delighted to announce the appointment of Dr Fabio Spreafico as our European Sales Manager.  Joining us from his previous role as Business Development Manager at BASF subsidiary, Metanomics Health GmbH in Berlin, Fabio brings over 20 years of scientific and business experience to the company. In his new role he will be based primarily near Milan, and will work to bring Gentronix and our offerings to new and existing customers in the European market. Enquires and contact details for Gentronix can be found at http://www.gentronix.co.uk/contact-us/

Read the rest of this news item

Gentronix is recruiting

Posted on March 1, 2016 by Chris Hughes

Gentronix is expanding and currently looking to recruit study investigators for the Ames and Micronucleus assays.  Further details are available on our careers page. Recruitment for these positions has now expired.

Read the rest of this news item